A buying opportunity has emerged in this agriculture stock, JPMorgan says

JPMorgan upgraded Corteva (CTVA) to Overweight with a $70 price target, citing a buying opportunity after the stock fell 9.1% following its announcement to split into two entities by H2 2026. Analyst Jeffrey Zekauskas views the sell-off as an undervaluation, believing the strategic separation, particularly for the crop chemicals business currently trading at a depressed 4x-6x EBITDA multiple, will unlock value, implying approximately 14% upside.

Analysis

Corteva's (CTVA) stock experienced a significant 9.1% decline following its announcement to separate into two distinct publicly traded entities, a process slated for completion in the second half of 2026. Despite this negative market reaction, JPMorgan has upgraded the stock to overweight, viewing the pullback as a mispricing that creates an attractive entry point. The bank's analyst, Jeffrey Zekauskas, maintains a $70 year-end price target, implying approximately 14% upside from the post-announcement closing price. The core of this bullish thesis rests on a sum-of-the-parts valuation, which suggests the market is undervaluing the future crop chemical business. According to JPMorgan's estimates, while the Seed company trades at a reasonable 13.5x EBITDA, the Crop Chemical segment is valued at a deeply discounted multiple of 6x 2025 EBITDA and 4x 2026 EBITDA. Zekauskas argues a more appropriate multiple for the crop chemical business would be in the 9x-10x range, at a premium to peer FMC, highlighting a substantial potential for a value re-rating upon separation.

Key Decisions for Investors

• Investors may consider the 9.1% share price decline as a tactical buying opportunity, aligning with JPMorgan's thesis that the market has overreacted and created a clear undervaluation.
• The primary driver for the investment thesis is the potential multiple re-rating of the Crop Chemical business post-spin; investors should monitor sentiment and valuation metrics for this segment relative to peers like FMC.
• Given the separation is not scheduled until the second half of 2026, this is a long-term value play that requires patience, as the catalyst for unlocking the perceived value is over two years away.